Psoriatic arthritis: Update on pathophysiology, assessment and management

Annals of the Rheumatic Diseases

Volumn 70, Issue SUPPL. 1, 2011, Pages

  Mease, Philip J ^a,b  

^a SWEDISH MEDICAL CENTER   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; ALEFACEPT; APREMILAST; BRIAKINUMAB; CD68 ANTIGEN; CERTOLIZUMAB PEGOL; CYCLOSPORIN A; DENOSUMAB; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; HLA B27 ANTIGEN; HLA DR7 ANTIGEN; INFLIXIMAB; JANUS KINASE INHIBITOR; LEFLUNOMIDE; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PSORALEN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; SALAZOSULFAPYRIDINE; STEROID; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; USTEKINUMAB; ANALGESIC AGENT; CORTICOSTEROID; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; IMMUNOSUPPRESSIVE AGENT; TUMOR NECROSIS FACTOR ALPHA;

ANKYLOSING SPONDYLITIS; ARTHROPATHY; CD4 CD8 RATIO; CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; COMORBIDITY; CONFERENCE PAPER; DISEASE ACTIVITY; DISEASE SEVERITY; DOSAGE SCHEDULE COMPARISON; ENTHESITIS; GASTROINTESTINAL SYMPTOM; GENETIC ASSOCIATION; HUMAN; HYPERTENSION; INFECTION; KIDNEY FAILURE; LIVER TOXICITY; NAIL DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEITIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; QUALITY OF LIFE; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN BIOPSY; SKIN DISEASE; SPINE DISEASE; SPONDYLITIS; SPONDYLOARTHROPATHY; SYNOVITIS; VISUAL ANALOG SCALE; CLINICAL EFFECTIVENESS; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; DACTYLITIS; DISEASE ASSOCIATION; DRUG APPROVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG RESPONSE; GENE; HLA B27 GENE; HLA B39 GENE; HLA CW6 GENE; HLA DQ3 GENE; HLA DR7 GENE; LOW DRUG DOSE; LYMPHOMA; MOLECULAR PATHOLOGY; MONOTHERAPY; OSTEOPOROSIS; PSORIASIS; DRUG ANTAGONISM; REVIEW;

ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; HUMANS; IMMUNOSUPPRESSIVE AGENTS; SPONDYLITIS; SYNOVITIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79953000642     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/ard.2010.140582     Document Type: Conference Paper

References (93)

1. Boudreau D, Bautista L, Uddin M, et al. Novel association of HCP5 gene in psoriatic arthritis [abstract]. Ann Rheum Dis 2010;69 (suppl 3):114.
2. Chandran V, Gladman DD. Update on biomarkers in psoriatic arthritis. Curr Rheumatol Rep 2010;12:288-94.
3. Kruithof E, Van den Bossche V, De Rycke L, et al. Distinct synovial immunopathologic characteristics of juvenile-onset spondylarthritis and other forms of juvenile idiopathic arthritis. Arthritis Rheum 2006;54:2594-604. (Pubitemid 44205021)
4. Reece RJ, Canete JD, Parsons WJ, et al. Distinct vascular patterns of early synovitis in psoriatic, reactive, and rheumatoid arthritis. Arthritis Rheum 1999;42:1481-4. (Pubitemid 30265607)
5. van Kuijk AW, Reinders-Blankert P, Smeets TJ, et al. Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment. Ann Rheum Dis 2006;65:1551-7. (Pubitemid 44799664)
6. Kane D, Gogarty M, O'leary J, et al. Reduction of synovial sublining layer inflammation and proinflammatory cytokine expression in psoriatic arthritis treated with methotrexate. Arthritis Rheum 2004;50:3286-95. (Pubitemid 39372006)
7. Goedkoop AY, Kraan MC, Teunissen MB, et al. Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. Ann Rheum Dis 2004;63:769-73. (Pubitemid 38850446)
8. Kruithof E, De Rycke L, Roth J, et al. Immunomodulatory effects of etanercept on peripheral joint synovitis in the spondylarthropathies. Arthritis Rheum 2005;52:3898-909. (Pubitemid 41798229)
9. Baeten D, Kruithof E, De Rycke L, et al. Infiltration of the synovial membrane with macrophage subsets and polymorphonuclear cells reflects global disease activity in spondyloarthropathy. Arthritis Res Ther 2005;7:R359-69.
10. Cañete JD, Santiago B, Cantaert T, et al. Ectopic lymphoid neogenesis in psoriatic arthritis. Ann Rheum Dis 2007;66:720-6. (Pubitemid 46846689)
11. Lories RJ, Derese I, Luyten FP, et al. Activation of nuclear factor kappa B and mitogen activated protein kinases in psoriatic arthritis before and after etanercept treatment. Clin Exp Rheumatol 2008;26:96-102. (Pubitemid 351385261)
12. Fernández-Sueiro JL, Willisch A, Pértega-Díaz S, et al. Evaluation of ankylosing spondylitis spinal mobility measurements in the assessment of spinal involvement in psoriatic arthritis. Arthritis Rheum 2009;61:386-92.
13. Gladman DD, Chandran V. Observational cohort studies: lessons learnt from the University of Toronto Psoriatic Arthritis Program. Rheumatology (Oxford) 2010.
14. Sturrock RD. Clinical utility of ultrasonography in spondyloarthropathies. Curr Rheumatol Rep 2009;11:317-20.
15. Girolomoni G, Gisondi P. Psoriasis and systemic inflammation: underdiagnosed enthesopathy. J Eur Acad Dermatol Venereol 2009;23 Suppl 1: 3-8.
16. McGonagle D, Lories RJ, Tan AL, et al. The concept of a "synovio-entheseal complex" and its implications for understanding joint inflammation and damage in psoriatic arthritis and beyond. Arthritis Rheum 2007;56:2482-91. (Pubitemid 47237267)
17. Benjamin M, Toumi H, Suzuki D, et al. Microdamage and altered vascularity at the enthesis-bone interface provides an anatomic explanation for bone involvement in the HLA-B27-associated spondylarthritides and allied disorders. Arthritis Rheum 2007;56:224-33. (Pubitemid 46106196)
18. McQueen F, Lassere M, Østergaard M. Magnetic resonance imaging in psoriatic arthritis: a review of the literature. Arthritis Res Ther 2006;8:207.
19. McQueen FM, Dalbeth N, Doyle A. MRI in psoriatic arthritis: insights into pathogenesis and treatment response. Curr Rheumatol Rep 2008;10:303-10.
20. Appel H, Kuhne M, Spiekermann S, et al. Immunohistochemical analysis of hip arthritis in ankylosing spondylitis: evaluation of the bone-cartilage interface and subchondral bone marrow. Arthritis Rheum 2006;54:1805-13. (Pubitemid 43877930)
21. Ritchlin CT, Haas-Smith SA, Li P, et al. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003;111:821-31. (Pubitemid 37074957)
22. Williamson L, Dockerty JL, Dalbeth N, et al. Clinical assessment of sacroiliitis and HLA-B27 are poor predictors of sacroiliitis diagnosed by magnetic resonance imaging in psoriatic arthritis. Rheumatology (Oxford) 2004;43:85-8. (Pubitemid 38088373)
23. Lories RJ, Derese I, Luyten FP. Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. J Clin Invest 2005;115:1571-9. (Pubitemid 40814665)
24. Rudwaleit M, van der Heijde D, Landewé R, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009;68:777-83.
25. Gladman DD, Mease PJ, Strand V, et al. Consensus on a core set of domains for psoriatic arthritis. J Rheumatol 2007;34:1167-70. (Pubitemid 46774868)
26. Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis 2009;68:1387-94.
27. Kavanaugh AF, Ritchlin CT. Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. J Rheumatol 2006;33:1417-21. (Pubitemid 44025162)
28. Mease P, Antoni C, Gladman DD, et al. Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 2005;64 (suppl 2):ii49-54.
29. Mease PJ. Assessment tools in psoriatic arthritis. J Rheumatol 2008;35:1426-30. (Pubitemid 352000798)
30. Gladman DD, Mease PJ, Healy P, et al. Outcome measures in psoriatic arthritis. J Rheumatol 2007;34:1159-66. (Pubitemid 46774867)
31. Feldman SR, Krueger G. Psoriasis assessment tools in clinical trials. Ann Rheum Dis 2005;64 (suppl 2):ii65-8.
32. Mease P, van der Heijde D. Joint damage in psoriatic arthritis: How is it assessed and can it be prevented? Int J Adv Rheumatol 2006;4:38-48.
33. Mease PJ, Menter MA. Quality-of-life issues in psoriasis and psoriatic arthritis: outcome measures and therapies from a dermatological perspective. J Am Acad Dermatol 2006;54:685-704.
34. Gladman DD, Inman RD, Cook RJ, et al. International spondyloarthritis interobserver reliability exercise-the INSPIRE study: I. Assessment of spinal measures. J Rheumatol 2007;34:1733-9. (Pubitemid 47267618)
35. Gladman DD, Inman RD, Cook RJ, et al. International spondyloarthritis interobserver reliability exercise-the INSPIRE study: II. Assessment of peripheral joints, enthesitis, and dactylitis. J Rheumatol 2007;34:1740-5. (Pubitemid 47267619)
36. Chandran V, Gottlieb A, Cook RJ, et al. International multi-center psoriasis and psoriatic arthritis reliability trial (GRAPPA-IMPART): Assessment of skin, joints, nails, and dactylitis. Arthritis and Rheum 2007;56:S789-99.
37. Mease P. Management of psoriatic arthritis: the therapeutic interface between rheumatology and dermatology. Curr Rheumatol Rep 2006;8:348-54. (Pubitemid 44638827)
38. Qureshi AA, Dominguez P, Duffin KC, et al. Psoriatic arthritis screening tools. J Rheumatol 2008;35:1423-5. (Pubitemid 352000797)
39. de Vlam K, Gottlieb AB, Fitzgerald O. Biological biomarkers in psoriatic disease. A review. J Rheumatol 2008;35:1443-8. (Pubitemid 352000801)
40. Duffin KC, Chandran V, Gladman DD, et al. Genetics of psoriasis and psoriatic arthritis: update and future direction. J Rheumatol 2008;35:1449-53. (Pubitemid 352000802)
41. Soriano ER, McHugh NJ. Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J Rheumatol 2006;33:1422-30. (Pubitemid 44025163)
42. Nash P. Therapies for axial disease in psoriatic arthritis. A systematic review. J Rheumatol 2006;33:1431-4. (Pubitemid 44025164)
43. Ritchlin CT. Therapies for psoriatic enthesopathy. A systematic review. J Rheumatol 2006;33:1435-8. (Pubitemid 44025165)
44. Helliwell PS. Therapies for dactylitis in psoriatic arthritis. A systematic review. J Rheumatol 2006;33:1439-41. (Pubitemid 44025166)
45. Strober BE, Siu K, Menon K. Conventional systemic agents for psoriasis. A systematic review. J Rheumatol 2006;33:1442-6. (Pubitemid 44025167)
46. Boehncke WH, Prinz J, Gottlieb AB. Biologic therapies for psoriasis. A systematic review. J Rheumatol 2006;33:1447-51. (Pubitemid 44025168)
47. Cassell S, Kavanaugh AF. Therapies for psoriatic nail disease. A systematic review. J Rheumatol 2006;33:1452-6.
48. Bakker MF, Jacobs JW, Verstappen SM, et al. Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Ann Rheum Dis 2007;66 (suppl 3):iii56-60.
49. Mease PJ, Chernoff D. Tighter control in RA: Exploring new paradigms. Clin Exp Rheumatol (In Press).
50. de Vlam K, Lories RJ. Remission in psoriatic arthritis. Curr Rheumatol Rep 2008;10:297-302.
51. Mumtaz A, Gallagher P, Kirby B, et al. Development of a composite disease activity index in psoriatic arthritis [abstract]. Ann Rheum Dis 2010;69 (suppl 3):115.
52. Schoels M, Aletaha D, Funovits J, et al. Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. Ann Rheum Dis 2010;69:1441-7.
53. Coates LC, Fransen J, Helliwell PS. Defining minimal disease activity in psoriatic arthritis: a proposed objective target for treatment. Ann Rheum Dis 2010;69:48-53.
54. Coates LC, Cook R, Lee KA, et al. Frequency, predictors, and prognosis of sustained minimal disease activity in an observational psoriatic arthritis cohort. Arthritis Care Res (Hoboken) 2010;62:970-6.
55. Coates LC, Helliwell PS. Validation of minimal disease activity criteria for psoriatic arthritis using interventional trial data. Arthritis Care Res (Hoboken) 2010;62:965-9.
56. Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005;64 (suppl 2):ii14-17.
57. Maksymowych WP, Landewé R, Tak PP, et al. Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteria. J Rheumatol 2009;36:1785-91.
58. Maksymowych WP, Fitzgerald O, Wells GA, et al. Proposal for levels of evidence schema for validation of a soluble biomarker reflecting damage endpoints in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and recommendations for study design. J Rheumatol 2009;36:1792-9.
59. Nash P, Clegg DO. Psoriatic arthritis therapy:NSAIDs and traditional DMARDs. Ann Rheum Dis 2005;64 (suppl 2):ii74-7.
60. Mease PJ. Psoriatic arthritis assessment and treatment update. Curr Opin Rheumatol 2009;21:348-55.
61. Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005;64:1150-7. (Pubitemid 41113349)
62. Abu-Shakra M, Gladman DD, Thorne JC, et al. Longterm methotrexate therapy in psoriatic arthritis: clinical and radiological outcome. J Rheumatol 1995;22:241-5.
63. Whiting-O'Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 1991;90:711-6.
64. Kalb RE, Strober B, Weinstein G, et al. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2009;60:824-37.
65. Raffayova H, Kungurov N, Baranauskaite A, et al. Infliximab plus methotrexate significantly improves rates of remission for methotrexate naive psoriatic arthritis (PsA) patients compared to methotrexate alone: The RESPOND trial [abstract]. Arthritis and Rheum 2009;60 (suppl 10):S470-1.
66. Karanikolas GN, Arida K, Komninou E, et al. Combination of adalimamab with cyclosporine-a against single therapy in refractory psoriatic arthritis: An interim analysis of an ongoing, 12-month open, three-arm, randomized trial. Ann Rheum Dis 2009;68:138-9.
67. Gibbs A, Gogarty M, Veale D, et al. Efficacy of anakinra (Kineret) in psoriatic arthritis, a clinical and immunohistological study. Ann Rheum Dis 2006;65:216.
68. Sterry W, Ortonne JP, Kirkham B, et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. BMJ 2010;340:c147.
69. Zaba LC, Cardinale I, Gilleaudeau P, et al. Amelioration of epidermal hyperplasia by TNF inhibition is associated with reduced Th17 responses. J Exp Med 2007;204:3183-94.
70. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2005;52:3279-89. (Pubitemid 41447111)
71. Mease PJ, Ory P, Sharp JT, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). Ann Rheum Dis 2009;68:702-9.
72. Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. Arthritis Rheum 2009;60:976-86.
73. Kavanaugh A, Mease P, Krueger GG, et al. Golimumab, a new, human, TNF alpha antibody, administered subcutaneously every 4 weeks in psoriatic arthritis patients: 104-week effiacay and safety results of the randomized, placebo-controlled GO-REVEAL study. Ann Rheum Dis 2009;68:136-37.
74. Kavanaugh A, van der Heidje D, Gladman D, et al. Golimumab inhibits progression of radiographic damage in patients with psoriatic arthritis: 52 week results from the GO-REVEAL study [abstract]. Ann Rheum Dis 2010;69 (suppl 3):116.
75. Van den Bosch F, Manger B, Goupille P, et al. Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. Ann Rheum Dis 2010;69:394-9.
76. Zochling J, van der Heijde D, Dougados M, et al. Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 2006;65:423-32.
77. Mease PJ, Gladman DD, Keystone EC. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebocontrolled study. Arthritis Rheum 2006;54:1638-45.
78. Mease PJ, Reich K. Alefacept with methotrexate for treatment of psoriatic arthritis: open-label extension of a randomized, double-blind, placebo-controlled study. J Am Acad Dermatol 2009;60:402-11.
79. Abrams JR, Lebwohl MG, Guzzo CA, et al. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999;103:1243-52.
80. Mease P, Genovese MC, Ritchlin C, et al. Abatacept in psoriatic arthritis: Results of a phase II study session [abstract]. Arthritis and Rheum 2009;60 (suppl 10):S472.
81. Krueger GG, Langley RG, Leonardi C, et al. A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis. N Engl J Med 2007;356:580-92. (Pubitemid 46220818)
82. Gottlieb A, Menter A, Mendelsohn A, et al. Ustekinumab, a human interleukin 12/23 monoclonal antibody, for psoriatic arthritis: randomised, double-blind, placebocontrolled, crossover trial. Lancet 2009;373:633-40.
83. Kimball AB, Gordon KB, Valdes JM, et al. Retreatment efficacy and long-term safety of the fully human, interleukin-12/23 monoclonal antibody ABT-874 in the treatment of moderate to severe psoriasis: 48-week results from a phase II trial. 17th Congress on the European Academy of Dermatology and Venereology, September, 2008, Paris, France.
84. McInnes IB, Gracie JA. Interleukin-15: a new cytokine target for the treatment of inflammatory diseases. Curr Opin Pharmacol 2004;4:392-7. (Pubitemid 38987067)
85. Mease P, Genovese M, Ritchlin C, et al. Rituximab in psoriatic arthritis: Results of an open label study [abstract]. Ann Rheum Dis 2010;69 (suppl 3):116.
86. Cohen SB, Dore RK, Lane NE, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelvemonth, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. Arthritis Rheum 2008;58:1299-309. (Pubitemid 351705919)
87. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermatol 2008;58:851-64. (Pubitemid 351509657)
88. Wong K, Gladman DD, Husted J, et al. Mortality studies in psoriatic arthritis: results from a single outpatient clinic. I. Causes and risk of death. Arthritis Rheum 1997;40:1868-72. (Pubitemid 27452539)
89. Han C, Robinson DW Jr, Hackett MV, et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol 2006;33:2167-72. (Pubitemid 44749774)
90. K imhi O, C aspi D, B ornstein N M, et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis. Semin Arthritis Rheum 2007;36:203-9.
91. Ku IA, Imboden JB, Hsue PY, et al. Rheumatoid arthritis: model of systemic inflammation driving atherosclerosis. Circ J 2009;73:977-85.
92. Tam L, Li EK, Shang Q, et al. TNF-alpha blcokade is associated with reduction of carotid intima-media thickness for patients with active psoriatic arthritis-A pilot study. Ann Rheum Dis 2009;68:659.
93. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 2009;361(5):496-509.